Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Pancreatic Neoplasms 10Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Lung Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 4Esophageal Neoplasms 4Endometrial Neoplasms 4Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Inflammatory Breast Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Neoplasms, Squamous Cell 2Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Brenner Tumor 2Adenocarcinoma of Lung 2

Interventions

Cisplatin 9pembrolizumab 8Radiotherapy, Intensity-Modulated 6Radiotherapy 5Carboplatin 5cemiplimab 4Paclitaxel 4durvalumab 3Surveys and Questionnaires 3Nivolumab 3tremelimumab 2Taxes 2Radiation 2olaparib 1niraparib 1lirilumab 1linrodostat 1fludarabine phosphate 1fludarabine 1dostarlimab 1bavituximab 1atezolizumab 1alpha-2'-deoxythioguanosine 1aldesleukin 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiotherapy, Image-Guided 1Proton Therapy 1Platinum Compounds 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Squamous Cell × Taxes × Clear all
NCT04391049 2026-01-30

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NRG Oncology

Phase 1 Active not recruiting
16 enrolled 15 charts

Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡